Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jaktinib
- Development stage
- Phase 3
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jaktinib is a novel small molecule inhibitor targeting Janus kinases (JAK1, JAK2, JAK3, TYK2) and activin A receptor type 1 (ACVR1). It blocks the JAK-STAT signaling pathway by inhibiting these kinases and thereby modulates immune responses and cytokine signaling. Additionally, inhibition of ACVR1 reduces hepcidin transcription to improve iron metabolism and anemia in myelofibrosis patients. Developed as a first-in-class drug in China for intermediate- or high-risk myelofibrosis (MF), it has also entered clinical trials for other indications such as alopecia areata, atopic dermatitis, psoriasis, and ankylosing spondylitis[2][3][4][6].
- Brand names
- jaktinib
- Other names
- 盐酸杰克替尼盐酸吉卡昔替尼Jaktinib hydrochloride
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)ACVR1 (Activin receptor type I)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on jaktinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jaktinib.